Silvia Hansel brings her dynamic attitude and problem-solving skills to her new position as Chief Operating Officer of the Geneva Biotech Center. Her background in customer and investor relations, as well as organization and administration nicely complements the pharmaceutical, medical and financial background of the other members of the GBC team. Silvia is expected to manage the day-to-day activities of the GBC, including being responsible for external communications, investor relations, as well as managing the agenda, meetings and documents of the GBC. Prior to her arrival at the GBC, Silvia was a board member and CEO of Kaleyde Pharmaceuticals and pursued numerous similar activities in cultural and charitable organizations.